Maharaj Nakorn Chiang Mai Hospital is a university teaching hospital, affiliated to the Faculty of Medicine of Chiang Mai University, located in Mueang Chiang Mai District, Chiang Mai Province.

There are 1,400 beds in Maharaj Nakorn Chiang Mai Hospital.

During the past decade, Maharaj Nakorn Chiang Mai Hospital conducted 76 clinical trials. In the 10-year time frame, 76 clinical trials started and 31 clinical trials were completed, i.e. on average, 40.8% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 21 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Maharaj Nakorn Chiang Mai Hospital" #1 sponsor was "Hoffmann-La Roche" with 16 trials, followed by "Chiang Mai University" with 15 trials sponsored, "Allergan" with 8 trials sponsored, "Actelion" with 3 trials sponsored and "Astellas Pharma Inc" with 3 trials sponsored. Other sponsors include 54 different institutions and companies that sponsored additional 50 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Maharaj Nakorn Chiang Mai Hospital" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "Basilea Pharmaceutica International Ltd" with 2 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator, "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 2 trials as a collaborator and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Maharaj Nakorn Chiang Mai Hospital" are "Hepatitis B" (5 trials), "Hepatitis B, Chronic" (5 trials), "Cerebral Palsy" (4 trials), "Gastroparesis" (4 trials) and "Muscle Spasticity" (4 trials). Many other conditions were trialed in "Maharaj Nakorn Chiang Mai Hospital" in a lesser frequency.

Most popular intervention types in "Maharaj Nakorn Chiang Mai Hospital" are "Drug" (76 trials), "Other" (16 trials), "Biological" (15 trials), "Procedure" (6 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "Cisplatin" (6 trials), "Gemcitabine" (5 trials), "Carboplatin" (4 trials) and "Pemetrexed" (4 trials). Other intervention names were less common.

The vast majority of trials in "Maharaj Nakorn Chiang Mai Hospital" are 96 trials for "All" genders, 6 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Maharaj Nakorn Chiang Mai Hospital". 1 are not yet recruiting, 14 are recruiting, 20 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 48 completed trials in Maharaj Nakorn Chiang Mai Hospital, 1 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Maharaj Nakorn Chiang Mai Hospital, 6 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 60 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 7 trials that are defined as “Not Applicable".